English: Yes, I'm very pleased and proud of the national approach that we've chosen to take here in Wales - a genuinely national approach based on clinical need being the criteria for access to PrEP. That's in contrast to the approach taken in both Northern Ireland and England, where there isn't a national approach and, of course, the Terrence Higgins Trust and others are fundraising to be able to make the funds available for people to actually be able to use PrEP. That isn't a challenge we have here. We now have, from the end of September, 697 people in Wales who've been prescribed PrEP, and 386 are currently taking the preventative treatment. There have been no new cases of HIV within that group of people, and that is a real success story for all of us. We do, though, recognise that about one in four people who are potentially eligible for PrEP don't come back for follow-up and don't actually take it up. So, part of our challenge, in research that is ongoing, is both to properly understand the impact of providing PrEP and to make sure that we continue to see that reduction in HIV, but also to try to understand why some people don't access PrEP when it is potentially available. There is a range of research, including funding that we provided to Cardiff University - £400,000 of funding - to carry out research into the behaviours of those who choose to take PrEP, because we do recognise that there is a high incidence of sexually transmitted infections being acquired by people who are taking PrEP, so it's actually getting to the right sort of cohort of people. I will, of course, though, in terms of your final point, happily update this place when we do have the results of either further incidents of the numbers of use, but, in particular, the research trials that we are already supporting.
Welsh: Ie, rwy'n falch iawn o'r dull cenedlaethol rydym wedi dewis ei fabwysiadu yma yng Nghymru - dull gwirioneddol genedlaethol sy'n seiliedig ar sicrhau mai angen clinigol yw'r maen prawf ar gyfer mynediad at broffylacsis cyn-gysylltiad. Mae hynny'n gwrthgyferbynnu â'r dull a fabwysiadwyd yng Ngogledd Iwerddon a Lloegr, lle nad oes dull cenedlaethol o weithredu ac wrth gwrs, mae Ymddiriedolaeth Terrence Higgins ac eraill yn codi arian i sicrhau bod arian ar gael i bobl ddefnyddio proffylacsis cyn-gysylltiad. Nid yw honno'n her sy'n ein hwynebu ni yma. Ers diwedd mis Medi, mae proffylacsis cyn-gysylltiad wedi'i bresgripsiynu ar gyfer 697 o bobl yng Nghymru, ac mae 386 yn cael triniaeth ataliol. Nid oes unrhyw achosion newydd o HIV wedi bod o fewn y grŵp hwnnw o bobl, ac mae hynny'n arwydd go iawn o lwyddiant i bob un ohonom. Er hynny, rydym yn cydnabod nad yw oddeutu un o bob pedwar o bobl a allai fod yn gymwys ar gyfer proffylacsis cyn-gysylltiad yn dod yn ôl am apwyntiad dilynol nac yn manteisio arno. Felly, rhan o'r her sy'n ein hwynebu, mewn gwaith ymchwil sy'n mynd rhagddo, yw deall yn iawn beth yw effaith darparu proffylacsis cyn-gysylltiad a sicrhau ein bod yn parhau i weld y gostyngiad o ran HIV, a cheisio deall hefyd pam nad yw rhai pobl yn manteisio ar broffylacsis cyn-gysylltiad pan allai fod ar gael. Ceir llawer o ymchwil, gan gynnwys cyllid a ddarparwyd gennym i Brifysgol Caerdydd - £400,000 o gyllid - i gyflawni ymchwil i ymddygiad y rhai sy'n dewis manteisio ar broffylacsis cyn-gysylltiad, oherwydd rydym yn cydnabod bod nifer uchel o achosion o heintiau a drosglwyddir yn rhywiol ymhlith pobl sy'n manteisio ar broffylacsis cyn-gysylltiad, felly mae'n ymwneud â chyrraedd y garfan iawn o bobl mewn gwirionedd. Ond o ran eich pwynt olaf, wrth gwrs, byddaf yn hapus i roi'r wybodaeth ddiweddaraf i'r lle hwn pan fydd gennym ganlyniadau o ran y niferoedd pellach sy'n dewis manteisio arno, ac yn benodol, canlyniadau'r treialon ymchwil rydym eisoes yn eu cefnogi.